Amendment: SEC Form SC 13G/A filed by Fulcrum Therapeutics Inc.
$FULC
Biotechnology: Pharmaceutical Preparations
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/12/2026 | $20.00 | Overweight | Analyst |
| 11/24/2025 | Buy | Truist | |
| 7/29/2025 | $4.00 → $12.00 | Neutral → Buy | H.C. Wainwright |
| 5/23/2025 | $12.00 | Market Perform → Outperform | Leerink Partners |
| 5/15/2025 | $10.00 | Neutral → Overweight | Cantor Fitzgerald |
| 9/13/2024 | $17.00 → $4.00 | Buy → Neutral | H.C. Wainwright |
| 9/12/2024 | $15.00 → $4.00 | Outperform → Sector Perform | RBC Capital Mkts |
| 9/12/2024 | $4.00 | Outperform → Market Perform | Leerink Partners |
4/A - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
Analyst initiated coverage of Fulcrum Therapeutics with a rating of Overweight and set a new price target of $20.00
Truist initiated coverage of Fulcrum Therapeutics with a rating of Buy
H.C. Wainwright upgraded Fulcrum Therapeutics from Neutral to Buy and set a new price target of $12.00 from $4.00 previously
S-8 - Fulcrum Therapeutics, Inc. (0001680581) (Filer)
10-K - Fulcrum Therapeutics, Inc. (0001680581) (Filer)
8-K - Fulcrum Therapeutics, Inc. (0001680581) (Filer)
― Announced positive 12-week results from the 20 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) ― ― 20 mg cohort demonstrated rapid and robust fetal hemoglobin (HbF) induction, with mean absolute HbF increasing by 12.2% from a baseline of 7.1% to 19.3% at Week 12, improvements in markers of hemolysis and anemia, and encouraging trends in vaso-occlusive crisis (VOC) reduction ― ― Fulcrum plans to initiate a potential registration-enabling trial in the second half of 2026 ― ― Ended 2025 with $352.3 million in cash, cash equivalents, and marketable securities; cash runway into 2029 ― CAMBRIDGE, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therap
― Mean absolute fetal hemoglobin (HbF) increased by 12.2% (from 7.1% to 19.3%) at Week 12 (n=12), representing a rapid, robust, and clinically relevant response, with progression toward pan-cellular HbF induction as F-cells increased from 31% to 63% ― ― 7 of 12 patients (58%) achieved absolute HbF levels ≥20%; all patients achieved at least a 6.5% absolute increase in HbF ― ― Improvements in markers of hemolysis, improved erythropoiesis, and a >1 g/dL increase in total hemoglobin ― ― 7 of 12 patients (58%) reported zero VOCs during the treatment period ― ― Pociredir was generally well-tolerated, with no treatment-related serious adverse events (SAEs) ― ― Fulcrum plans to initiate a pote
CAMBRIDGE, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, will host a conference call and webcast on Tuesday, February 24, 2026 beginning at 8:00 a.m. ET to present 12-week results from the 20 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease. Members of Fulcrum management will be joined by Dr. Martin Steinberg, Professor of Medicine, Pediatrics, Pathology and Laboratory Medicine at Boston University Chobanian and Avedisian School of Medicine. To register for
― Mean absolute fetal hemoglobin (HbF) increased by 12.2% (from 7.1% to 19.3%) at Week 12 (n=12), representing a rapid, robust, and clinically relevant response, with progression toward pan-cellular HbF induction as F-cells increased from 31% to 63% ― ― 7 of 12 patients (58%) achieved absolute HbF levels ≥20%; all patients achieved at least a 6.5% absolute increase in HbF ― ― Improvements in markers of hemolysis, improved erythropoiesis, and a >1 g/dL increase in total hemoglobin ― ― 7 of 12 patients (58%) reported zero VOCs during the treatment period ― ― Pociredir was generally well-tolerated, with no treatment-related serious adverse events (SAEs) ― ― Fulcrum plans to initiate a pote
CAMBRIDGE, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, will host a conference call and webcast on Tuesday, February 24, 2026 beginning at 8:00 a.m. ET to present 12-week results from the 20 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease. Members of Fulcrum management will be joined by Dr. Martin Steinberg, Professor of Medicine, Pediatrics, Pathology and Laboratory Medicine at Boston University Chobanian and Avedisian School of Medicine. To register for
CAMBRIDGE, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the "Company") (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that its third quarter 2025 financial results will be released on Wednesday, October 29, 2025, before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on recent corporate developments. Individuals may register for the conference call by clicking the link here. Once registered, participants will receive dial-in details
4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
CAMBRIDGE, Mass., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced the appointment of Isabel Kalofonos as chief commercial officer and Heather Faulds as chief regulatory affairs & quality assurance officer. Together, Ms. Kalofonos and Ms. Faulds will be instrumental in advancing losmapimod towards a New Drug Application (NDA) submission and preparing for commercial launch. "I am excited to welcome Isabel to our leadership team as we continue to advance towards the potential approval a
―Industry veteran with late-stage clinical development, medical affairs, and regulatory experience; well-positioned to advance losmapimod towards a potential regulatory submission and approval ― ― Interim Chief Medical Officer, Iain Fraser, MBChB, DPhil, will continue to serve on Fulcrum's executive leadership team as senior vice president (SVP) of early development ― CAMBRIDGE, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced the appointment of Patrick Horn, M.D., Ph.D., as
CAMBRIDGE, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced the appointment of Alan A. Musso as chief financial officer, effective August 7, 2023. A 30-year veteran in the life sciences industry, Mr. Musso has held numerous financial and operational leadership positions over the course of his career. "We are delighted to welcome Alan to our executive leadership team," said Alex C. Sapir, president and chief executive officer at Fulcrum Therapeutics. "Alan's wealth of industry experience and impressive track record
SC 13G/A - Fulcrum Therapeutics, Inc. (0001680581) (Subject)
SC 13G/A - Fulcrum Therapeutics, Inc. (0001680581) (Subject)
SC 13G/A - Fulcrum Therapeutics, Inc. (0001680581) (Subject)